Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany

Journal of Neuro-oncology
Albrecht WaschkeRolf Kalff

Abstract

Concomitant radiochemotherapy followed by six cycles of temozolomide (= short term) is considered as standard therapy for adults with newly diagnosed glioblastoma. In contrast, open-end administration of temozolomide until progression (= long-term) is proposed by some authors as a viable alternative. We aimed to determine the cost-effectiveness of long-term temozolomide therapy for patients newly diagnosed with glioblastoma compared to standard therapy. A Markov model was constructed to compare medical costs and clinical outcomes for both therapy types over a time horizon of 60 months. Transition probabilities for standard therapy were calculated from randomized controlled trial data by Stupp et al. The data for long-term temozolomide therapy was collected by matching a cohort treated in the Department of Neurosurgery at Jena University Hospital. Health utilities were obtained from a previous cost utility study. The cost perspective was based on health insurance. The base case analysis showed a median overall survival of 17.1 months and a median progression-free survival of 7.4 months for patients in the long-term temozolomide therapy arm. The cost-effectiveness analysis using all base case parameters in a time-dependent Markov...Continue Reading

References

Oct 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·F A Sonnenberg, J R Beck
Mar 8, 1998·PharmacoEconomics·A Briggs, M Sculpher
Mar 16, 2000·Health Affairs·P J NeumannR H Chapman
Jan 11, 2001·The New England Journal of Medicine·L M DeAngelis
Jul 30, 2003·Archives of Internal Medicine·Peter A UbelA Mark Fendrick
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 3, 2005·The Journal of Bone and Joint Surgery. American Volume·Carmen A BrauerPeter J Neumann
Aug 16, 2005·PharmacoEconomics·Janne A MartikainenPia Vihinen
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin H CohenRichard Pazdur
Dec 3, 2005·The Lancet Oncology·Martin J B TaphoornUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jul 11, 2006·Journal of Health and Social Behavior·Jessica A Kelley-MooreBoaz Kahana
Nov 17, 2009·Plastic and Reconstructive Surgery·Kevin C ChungMelissa J Shauver
Nov 17, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Chris P LeeStefanos A Zenios
Feb 24, 2010·Journal of Cancer Research and Clinical Oncology·Marcel SeizJochen Tuettenberg
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Nov 3, 2010·British Medical Bulletin·Sarah J Whitehead, Shehzad Ali
Dec 7, 2010·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Ravinder MohanPaul Schellhammer
Jun 25, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·C BalañáM Gil
Feb 18, 2014·Journal of Community Health Nursing·Linda M CulyerKathleen A Kelly
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruno Kovic, Feng Xie
Mar 17, 2017·Neurology·Dorothee GramatzkiMichael Weller
Apr 1, 2017·The Oncologist·Marco SkardellyGhazaleh Tabatabai

❮ Previous
Next ❯

Citations

Mar 24, 2020·The Cochrane Database of Systematic Reviews·Catherine HannaRobin Grant
Nov 2, 2020·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Martin ConnockXavier Armoiry
Nov 14, 2020·European Journal of Cancer Care·Edna KeeneyWilliam Hollingworth

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.